Johnson Matthey Inc. v. Noven Pharmaceuticals, Inc., No. 2:07-cv-00260 (E.D. Tex. July 21, 2009)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

I. Introduction In this case, the plaintiff, Johnson Matthey Inc. (“JM”), contends that the defendants, Noven Pharmaceuticals, Inc. (“Noven”), Shir e US Inc., and Shire Pharmaceuticals Ireland Limited (“Shire”) (collectively, “defendants”), in fringe claims 1 and 2 of United States Patent No. 6,096,760 (“the ‘760 patent”). This memorandum addresses the par ties’ various claim construction disputes. The memorandum will first briefly address the technology at issue in the case and then turn to the merits of the claim construction issues. II.